Log in to save to my catalogue

Sotorasib for Lung Cancers with KRAS p.G12C Mutation

Sotorasib for Lung Cancers with KRAS p.G12C Mutation

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9116274

Sotorasib for Lung Cancers with KRAS p.G12C Mutation

About this item

Publication information

Publisher

United States: Massachusetts Medical Society

More information

Scope and Contents

Contents

Sotorasib is a selective irreversible inhibitor of the G12C-activated
KRAS
oncogene, present in approximately 13% of non–small-cell lung cancers. In a single-group, phase 2 trial involving 126 patients with previously treated
KRAS
p.G12C–mutated NSCLC, 37% had a response (median duration, 11 months). One fifth of patients had grade 3 to...

Alternative Titles

Full title

Sotorasib for Lung Cancers with KRAS p.G12C Mutation

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9116274

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9116274

Other Identifiers

ISSN

0028-4793,1533-4406

E-ISSN

1533-4406

DOI

10.1056/NEJMoa2103695

How to access this item